PALM INTRANET

Day : Monday
Date: 2/13/2006
Time: 13:11:49

Inventor Information for 10/807023

Inventor Name	City	State/Country
CHEN, SHIRLYNN	SOMERS	NEW YORK
MEI, XIAOHUI	HIGHLAND MILLS	NEW YORK
WANG, ZEREN	SOUTHBURY	CONNECTICUT

Appln Info | Contents | Petition Info | Atty/Agent Info | Continuity Data | Foreign Data | Inver

Search Another: Application# [ ] Search **or Patent#** [ ] Search
PCT / [ ] / [ ] Search **or PG PUBS #** [ ] Search
Attorney Docket # [ ] Search
Bar Code # [ ] Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

```
=> d his ful

     (FILE 'HOME' ENTERED AT 16:27:31 ON 13 FEB 2006)

     FILE 'REGISTRY' ENTERED AT 16:27:59 ON 13 FEB 2006
L1             STRUCTURE UPLOADED
L2          18 SEA SSS SAM L1
L3         351 SEA SSS FUL L1

     FILE 'HCAPLUS, USPATFULL, USPAT2' ENTERED AT 16:28:44 ON 13 FEB 2006
L4          65 SEA PLU=ON  L3
L5          59 DUP REM L4 (6 DUPLICATES REMOVED)
                   ANSWERS '1-42' FROM FILE HCAPLUS
                   ANSWERS '43-59' FROM FILE USPATFULL
L6          50 SEA PLU=ON  L5 AND (PD<20040323 OR PRD<20040323)
L7          21 SEA PLU=ON  L5 AND (PD<20030323 OR PRD<20030323)

     FILE 'REGISTRY' ENTERED AT 16:30:47 ON 13 FEB 2006
L8           1 SEA PLU=ON  77-86-1/RN
               SET LINE 250
               SET DETAIL OFF
               SET LINE LOGIN
               SET DETAIL LOGIN

     FILE 'HCAPLUS, USPATFULL, USPAT2' ENTERED AT 16:31:33 ON 13 FEB 2006

     FILE 'REGISTRY' ENTERED AT 16:31:41 ON 13 FEB 2006
L9             SEL PLU=ON  L8 1- CHEM :      50 TERMS

     FILE 'HCAPLUS, USPATFULL, USPAT2' ENTERED AT 16:31:41 ON 13 FEB 2006
L10     300397 SEA PLU=ON  L9
L11     300534 SEA PLU=ON  L8 OR L10
L12         10 SEA PLU=ON  L7 AND L11
               D L7 1-21 IBIB ABS
L13       3364 SEA PLU=ON  ((SODIUM OR POTASSIUM OR ALUMINUM OR MAGNESIUM)
               (W) HYDROXIDE) AND (PROPYLENE (W) GLYCOL) AND (CAPRYL OR
               CAPRIC)
L14       1013 SEA PLU=ON  L13 AND L11
L15        687 SEA PLU=ON  L14 AND (ETHANOL (P) WATER)
L16        222 SEA PLU=ON  L15 AND (TOCOPHERYL OR (VITAMIN (W) E))
L*** DEL   222 L15 (W) (TOCOPHERYL OR (VITAMIN (W) E))
L17          0 SEA PLU=ON  ((SODIUM OR POTASSIUM OR ALUMINUM OR MAGNESIUM)
               (W) HYDROXIDE) (W) (PROPYLENE (W) GLYCOL) (W) (CAPRYL OR
               CAPRIC)
L18          0 SEA PLU=ON  L16 AND L12
L19          0 SEA PLU=ON  L16 AND L7
L20         13 SEA PLU=ON  L7 AND PHARMACEUTICAL


     FILE HOME

     FILE REGISTRY
     Property values tagged with IC are from the ZIC/VINITI data file
     provided by InfoChem.

     STRUCTURE FILE UPDATES:   12 FEB 2006  HIGHEST RN 874108-28-8
     DICTIONARY FILE UPDATES:  12 FEB 2006  HIGHEST RN 874108-28-8

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

     TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005
```

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

FILE HCAPLUS
FILE COVERS 1907 - 13 Feb 2006 VOL 144 ISS 8
FILE LAST UPDATED: 12 Feb 2006 (20060212/ED)

FILE USPATFULL
FILE COVERS 1971 TO PATENT PUBLICATION DATE: 9 Feb 2006 (20060209/PD)
FILE LAST UPDATED: 9 Feb 2006 (20060209/ED)
CA INDEXING IS CURRENT THROUGH 9 Feb 2006 (20060209/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 9 Feb 2006 (20060209/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2005

FILE USPAT2
FILE COVERS 2001 TO PUBLICATION DATE: 9 Feb 2006 (20060209/PD)
FILE LAST UPDATED: 9 Feb 2006 (20060209/ED)
CA INDEXING IS CURRENT THROUGH 9 Feb 2006 (20060209/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 9 Feb 2006 (20060209/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2005

=> d que sta
L1 STR



Structure attributes must be viewed using STN Express query preparation.

L3	351	SEA FILE=REGISTRY SSS FUL L1
L4	65	SEA L3
L5	59	DUP REM L4 (6 DUPLICATES REMOVED)
L7	21	SEA L5 AND (PD<20030323 OR PRD<20030323)
L20	13	SEA L7 AND PHARMACEUTICAL

H:\STN queries\10807023.str





chain nodes :
6 18 20 21 22 33 35
ring nodes :
1 2 3 4 5 7 8 9 10 11 12 13 14 15 16 17 19 23 24 25 26
27 28 29 30 31 32 34 36
chain bonds :
3-6 6-7 17-18 19-20 20-21 21-22 31-33 34-35
ring bonds :
1-2 1-5 1-17 2-3 3-4 4-5 5-34 7-8 7-12 8-9 9-10 10-11 11-12
11-13 12-16 13-14 14-15 15-16 17-19 19-23 23-24 24-25 25-26 26-27
27-28 28-29 29-30 30-31 30-32 31-32 31-36 34-36
exact/norm bonds :
1-2 1-5 1-17 2-3 3-4 3-6 4-5 5-34 6-7 7-8 7-12 8-9 9-10 10-11
11-12 11-13 12-16 13-14 14-15 15-16 17-18 17-19 19-20 19-23 20-21
21-22 23-24 24-25 25-26 26-27 27-28 28-29 29-30 30-31 30-32 31-32
31-33 31-36 34-35 34-36

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:Atom 8:Atom 9:Atom
10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom
18:CLASS 19:Atom 20:CLASS 21:CLASS 22:CLASS 23:Atom 24:Atom 25:Atom
26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom 32:Atom 33:CLASS
34:Atom 35:CLASS 36:Atom

> d l7 1-21 ibib abs

L7 ANSWER 1 OF 21 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:392478 HCAPLUS
DOCUMENT NUMBER: 140:400031
TITLE: Macrocyclic compound-containing compositions for the treatment of infection by Flaviviridae viruses
INVENTOR(S): Lamarre, Daniel; Lagace, Lisette
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany
SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
WO 2004039833	A1	20040513	WO 2003-CA1634		20031024	<--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW						
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG						
US 2005159345	A1	20050721	US 2003-687204		20031016	<--
CA 2498642	AA	20040513	CA 2003-2498642		20031024	<--
EP 1558633	A1	20050803	EP 2003-809665		20031024	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK						
BR 2003015781	A	20050913	BR 2003-15781		20031024	<--
NO 2005002580	A	20050720	NO 2005-2580		20050527	<--
PRIORITY APPLN. INFO.:			US 2002-421900P	P	20021029	<--
			US 2003-442769P	P	20030127	<--
			WO 2003-CA1634	W	20031024	

OTHER SOURCE(S): MARPAT 140:400031
GI



I

AB The invention relates to macrocyclic compds. I [A is alkyl or cycloalkyl; B is Ph or thiazolyl, which may be substituted by alkylamino or alkanoylamino; R is OH or NHSO2R2, where R2 is (un)substituted alkyl, cycloalkyl or aryl] or their pharmaceutically-acceptable salts for the treatment of a mammal infected with a virus of the Flaviviridae family. Thus, IC50 values for compound I [A is cyclopentyl, B is 2-(isopropylamino)-4-thiazolyl, R is OH] against HCV NS3-NS4A protease are shown graphically.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 21 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:370958 HCAPLUS
DOCUMENT NUMBER: 140:357673
TITLE: Preparation of macrocyclic peptides active against the hepatitis C virus
INVENTOR(S): Llinas-Brunet, Montse; Bailey, Murray D.
PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.h., Germany
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037855	A1	20040506	WO 2003-CA1604	20031020 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005075279	A1	20050407	US 2003-686755	20031016 <--
CA 2498572	AA	20040506	CA 2003-2498572	20031020 <--
EP 1558632	A1	20050803	EP 2003-809217	20031020 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.:
US 2002-421414P P 20021025 <--
US 2002-433820P P 20021216 <--
US 2003-442768P P 20030127 <--
WO 2003-CA1604 W 20031020

OTHER SOURCE(S): MARPAT 140:357673
GI



I

AB Macrocyclic peptides I [R1 is (un)substituted alkyl, cycloalkyl, alkylcycloalkyl, aryl or heteroaryl] or their pharmaceutically-acceptable salts were prepared as inhibitors of the hepatitis C virus (HCV) NS3 protease. Thus, I (R = Me) was prepared by a multistep sequence involving peptide coupling, olefin metathesis to form the macrocycle and methanesulfonamidation.

L7 ANSWER 3 OF 21 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:310970 HCAPLUS
DOCUMENT NUMBER: 140:327091
TITLE: Potent inhibitor of HCV serine protease
INVENTOR(S): Chen, Shirlynn; Nehmiz, Gerhard; Croenlein, Jens Oliver; Steinmann, Gerhard; Gunn, Jocelyn Abella; Costa, Phuong Do
PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004030670	A1	20040415	WO 2003-US30402	20030925 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004138109	A1	20040715	US 2003-663220	20030916 <--
CA 2500259	AA	20040415	CA 2003-2500259	20030925 <--

EP 1549311	A1	20050706	EP 2003-770478		20030925 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003014828	A	20050802	BR 2003-14828		20030925 <--
NO 2005002130	A	20050429	NO 2005-2130		20050429 <--
PRIORITY APPLN. INFO.:			US 2002-414940P	P	20020930 <--
			US 2002-421904P	P	20021029 <--
			US 2002-433834P	P	20021216 <--
			US 2003-443662P	P	20030130 <--
			WO 2003-US30402	W	20030925

GI



I

AB Disclosed are oral pharmaceutical compns., kits and methods of treating and preventing Hepatitis C Viral (HCV) infections wherein Compound (I), a potent inhibitor of HCV serine protease, or a pharmaceutically acceptable salt thereof, is administered in a selected dosage range. Also disclosed are the use of I or a pharmaceutically acceptable salt thereof, as a control substance for validating an HCV replication assay and also as a control substance for determining the relative effectiveness of one or more substances, alone or in combination, to inhibit the replication of HCV.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 21 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:252197 HCAPLUS
DOCUMENT NUMBER: 140:281350
TITLE: Spiro compounds for inhibiting the first-pass effect
INVENTOR(S): Harris, James W.
PATENT ASSIGNEE(S): Bioavailability System, LLC, USA
SOURCE: U.S. Pat. Appl. Publ., 133 pp., Cont.-in-part of U.S.

Ser. No. 793,416.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004058982	A1	20040325	US 2003-422848	20030425 <--
US 6248776	B1	20010619	US 1999-251467	19990217 <--
US 6476066	B1	20021105	US 2001-793416	20010227 <--
US 2005214366	A1	20050929	US 2005-81024	20050316 <--

PRIORITY APPLN. INFO.:
US 1999-251467 A3 19990217 <--
US 2001-793416 A2 20010227 <--
US 1997-56382P P 19970826 <--
US 1997-997259 A2 19971223 <--
US 2003-422848 B1 20030425

OTHER SOURCE(S): MARPAT 140:281350
GI



I

AB Compns., methods, etc. for addressing the first-pass effect are presented. An example compound prepared was I. Also processing citrus oils to obtain the compds. is given as examples as well as assessment of human cytochrome P 450-mediated biotransformation.

L7 ANSWER 5 OF 21 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:142968 HCAPLUS
DOCUMENT NUMBER: 140:193056
TITLE: Combinations of active agents with p38 MAP kinase inhibitors, pharmaceutical compositions, and use in the treatment of cytokine-mediated diseases
INVENTOR(S): Simianer, Stefan; Bilbault, Pascal; Cappola, Michael L.; Way, Susan Lynn
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA; Boehringer Ingelheim France
SOURCE: PCT Int. Appl., 168 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014387	A1	20040219	WO 2003-US25341	20030812 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004110755	A1	20040610	US 2003-638702		20030811 <--
CA 2497448	AA	20040219	CA 2003-2497448		20030812 <--
EP 1530477	A1	20050518	EP 2003-785255		20030812 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
JP 2006501218	T2	20060112	JP 2004-528105		20030812 <--
PRIORITY APPLN. INFO.:			US 2002-403115P	P	20020813 <--
			WO 2003-US25341	W	20030812

GI



I

AB The invention relates to pharmaceutical combination therapies based on p38 kinase inhibitors and another active ingredients, pharmaceutical compns. comprising such combinations, processes for preparing them, and their use in the treatment of cytokine-mediated diseases. Preparation of I (BIRB 796 BS) is described.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 21 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:950022 HCAPLUS
DOCUMENT NUMBER: 140:16973
TITLE: Preparation of macrocyclic peptides which are active against hepatitis C virus
INVENTOR(S): Llinas-Brunet, Montse; Gorys, Vida J.
PATENT ASSIGNEE(S): Boehringer Ingelheim (Canada) Ltd., Can.
SOURCE: U.S. Pat. Appl. Publ., 21 pp., Cont.-in-part of U.S. Ser. No. 320,978.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003224977	A1	20031204	US 2003-353894	20030129 <--
CA 2369711	AA	20030730	CA 2002-2369711	20020130
US 2003181363	A1	20030925	US 2002-320978	20021217 <--
PRIORITY APPLN. INFO.:			CA 2002-2369711 A	20020130 <--
			US 2002-320978 A2	20021217 <--

OTHER SOURCE(S): MARPAT 140:16973
GI



I

AB Macrocyclic peptides I [R1 is OH or NHSO2R1A, where R1A is (cyclo)alkyl, alkylcycloalkyl, or aryl which are optionally substituted from 1 to 3 times with halo, cyano, nitro, alkoxy, etc.; R2 is cycloalkyl] or their pharmaceutically-acceptable salt were prepared as inhibitors of the HCV NS3 protease. Thus, I (R1 = OH, R2 = cyclopentyl) was prepared and shown to have IC50 < 0.01 μM in the NS3-NS4A protease assay and EC50 < 0.01 μM in the cell-based HCV RNA replication assay.

L7 ANSWER 7 OF 21 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:886572 HCAPLUS
DOCUMENT NUMBER: 140:122161
TITLE: An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus
AUTHOR(S): Lamarre, Daniel; Anderson, Paul C.; Bailey, Murray; Beaulieu, Pierre; Bolger, Gordon; Bonneau, Pierre; Boes, Michael; Cameron, Dale R.; Cartier, Mireille; Cordingley, Michael G.; Faucher, Anne-Marie; Goudreau, Nathalie; Kawai, Stephen H.; Kukolj, George; Lagace, Lisette; LaPlante, Steven R.; Narjes, Hans; Poupart, Marc-Andre; Rancourt, Jean; Sentjens, Roel E.; St. George, Roger; Simoneau, Bruno; Steinmann, Gerhard; Thibeault, Diane; Tsantrizos, Youla S.; Weldon, Steven M.; Yong, Chan-Loi; Llinas-Brunet, Montse
CORPORATE SOURCE: Departments of Biological Sciences, Boehringer

Ingelheim (Canada) Ltd, Laval, QC, H7S 2G5, Can.
SOURCE: Nature (London, United Kingdom) (2003), 426(6963), 186-189
CODEN: NATUAS; ISSN: 0028-0836
PUBLISHER: Nature Publishing Group
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Hepatitis C virus (HCV) infection is a serious cause of chronic liver disease worldwide with more than 170 million infected individuals at risk of developing significant morbidity and mortality. Current interferon-based therapies are suboptimal especially in patients infected with HCV genotype 1, and they are poorly tolerated, highlighting the unmet medical need for new therapeutics. The HCV-encoded NS3 protease is essential for viral replication and has long been considered an attractive target for therapeutic intervention in HCV-infected patients. Here we identify a class of specific and potent NS3 protease inhibitors and report the evaluation of BILN 2061, a small mol. inhibitor biol. available through oral ingestion and the first of its class in human trials. Administration of BILN 2061 to patients infected with HCV genotype 1 for 2 days resulted in an impressive reduction of HCV RNA plasma levels, and established proof-of-concept in humans for an HCV NS3 protease inhibitor. Our results further illustrate the potential of the viral-enzyme-targeted drug discovery approach for the development of new HCV therapeutics.
REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 21 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:648255 HCAPLUS
DOCUMENT NUMBER: 139:197768
TITLE: Preparation of macrocyclic peptides active against the hepatitis C virus
INVENTOR(S): Tsantrizos, Youla S.; Cameron, Dale R.; Faucher, Anne-Marie; Ghiro, Elise; Goudreau, Nathalie; Halmos, Teddy; Llinas-Brunet, Montse
PATENT ASSIGNEE(S): Boehringer Ingelheim (Canada) Ltd., Can.
SOURCE: U.S., 90 pp., Cont.-in-part of U.S. Ser. No. 542,675, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
US 6608027	B1	20030819	US 2001-760946		20010116	<--
EP 1437362	A1	20040714	EP 2004-9264		20000403	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY						
US 2004002448	A1	20040101	US 2003-358726		20030205	<--
PRIORITY APPLN. INFO.:			US 1999-128011P	P	19990406	<--
			US 2000-542675	B2	20000403	<--
			EP 2000-913999	A3	20000403	<--
			US 2001-760946	A1	20010116	<--

OTHER SOURCE(S): MARPAT 139:197768
GI



I

AB Macrocyclic peptides I [W = CH or N; R21 = H, halo, alkyl, cycloalkyl, haloalkyl, alkoxy, cycloalkoxy, hydroxy, or an amino group; R22 = H, halo, alkyl, cycloalkyl, haloalkyl, thioalkyl, alkoxy, cycloalkoxy, alkoxyalkyl, cycloalkyl, aryl or heteroaryl; R3 = hydroxy, NH2, aryl- or heteroarylamino, NHCOR32, CONHR32, CO2R32, where R32 is alkyl or cycloalkyl; D is a 5 to 10-atom saturated or unsatd. alkylene chain optionally containing one to three heteroatoms independently selected from: O, S, or NH or substituted imino; R4 = H or from one to three substituents at any carbon atom of chain D; A is an amide or carboxylic acid group or a pharmaceutically acceptable salt or ester; two diastereomers may exist at the cyclopropane moiety] were prepared which are active in-vitro and in cellular assays against the NS3 protease of the hepatitis C virus. Thus, macrocyclic peptide I [W = N; R21, R22, R4 = H; A = CO2H; R3CH-D = (S)-(Me3CO2CNH)CH(CH2)3CH:CH(CH2)2-E (syn to acid)] was prepared and showed IC50 > 0.1 μM in the full-length NS3-NS4A heterodimer protein fluorogenic assay.

REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 9 OF 21 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:633516 HCAPLUS
DOCUMENT NUMBER: 139:185670
TITLE: Pharmaceutical compositions for hepatitis C viral protease inhibitors
INVENTOR(S): Chen, Shirlynn; Mei, Xiaohui
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003066103	A1	20030814	WO 2003-US3380	20030205 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003195228	A1	20031016	US 2003-357919	20030204 <--
US 6828301	B2	20041207		
CA 2472249	AA	20030814	CA 2003-2472249	20030205 <--
AU 2003208989	A1	20030902	AU 2003-208989	20030205 <--
EP 1474172	A1	20041110	EP 2003-707713	20030205 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003007524	A	20041221	BR 2003-7524	20030205 <--
JP 2005518423	T2	20050623	JP 2003-565526	20030205 <--
ZA 2004005064	A	20050530	ZA 2004-5064	20040625 <--
NO 2004003722	A	20040906	NO 2004-3722	20040906 <--
PRIORITY APPLN. INFO.:			US 2002-355694P P	20020207 <--
			WO 2003-US3380 W	20030205 <--

OTHER SOURCE(S): MARPAT 139:185670

GI



I

AB Disclosed are pharmaceutical compns. of hepatitis C viral protease inhibitors having improved bioavailability, and methods of using these compns. for inhibiting the replication of the hepatitis C virus (HCV) and for the treatment of an HCV infection. These compns. include co-solvent systems, lipid based systems, solid dispersions and granulations, and all comprise the hepatitis C viral protease inhibitor, at least one pharmaceutically acceptable amine and optionally one or more addnl. ingredients. A composition contained I 4, tromethamine 3.2, water 44.8, ethanol 21.3, and propylene glycol 26.7 weight/weight%.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 10 OF 21 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:610478 HCAPLUS
DOCUMENT NUMBER: 139:164979
TITLE: Preparation of macrocyclic peptides which are active

against hepatitis C virus

INVENTOR(S): Llinas-Brunet, Montse; Gorys, Vida J.
PATENT ASSIGNEE(S): Boehringer Ingelheim (Canada) Ltd., Can.
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003064455	A2	20030807	WO 2003-CA89	20030124 <--
WO 2003064455	A3	20040205		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2369711	AA	20030730	CA 2002-2369711	20020130
CA 2474035	AA	20030807	CA 2003-2474035	20030124 <--
EP 1472278	A2	20041103	EP 2003-700743	20030124 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003007297	A	20041221	BR 2003-7297	20030124 <--
CN 1639187	A	20050713	CN 2003-805484	20030124 <--
JP 2005524632	T2	20050818	JP 2003-564075	20030124 <--
ZA 2004005639	A	20050701	ZA 2004-5639	20040715 <--
NO 2004003591	A	20040827	NO 2004-3591	20040827 <--

PRIORITY APPLN. INFO.:		CA 2002-2369711	A	20020130 <--
		WO 2003-CA89	W	20030124 <--

OTHER SOURCE(S): MARPAT 139:164979
GI



I

AB Macrocyclic peptides I [R1 is OH or NHSO2R1A, where R1A is (cyclo)alkyl, alkylcycloalkyl, or aryl which are optionally substituted from 1 to 3 times with halo, cyano, nitro, alkoxy, etc.; R2 is cycloalkyl] or their pharmaceutically-acceptable salt were prepared as inhibitors of the HCV NS3 protease. Thus, I (R1 = OH, R2 = cyclopentyl) was prepared and shown to have IC50 < 0.01 μM in the NS3-NS4A protease assay and EC50 < 0.01 μM in the cell-based HCV RNA replication assay.

L7 ANSWER 11 OF 21 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:511084 HCAPLUS
DOCUMENT NUMBER: 139:69527
TITLE: Preparation of macrocyclic compounds as inhibitors of hepatitis C virus
INVENTOR(S): Campbell, Jeffrey Allen; Good, Andrew Charles
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 225 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003053349	A2	20030703	WO 2002-US39926	20021213 <--
WO 2003053349	A3	20040115		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004038872	A1	20040226	US 2002-317451	20021212 <--
US 6867185	B2	20050315		

EP 1455809 A2 20040915 EP 2002-795860 20021213 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
PRIORITY APPLN. INFO.: US 2001-344080P P 20011220 <--
US 2002-382103P P 20020520 <--
WO 2002-US39926 W 20021213 <--
OTHER SOURCE(S): MARPAT 139:69527
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to macrocyclic compds. I [R1 = (cyclo)alkyl; R2 = H, halo, alkyl, alkoxy, cycloalkoxy, (un)substituted aryl or heterocyclyl; R3 = H, halo, CF3, alkoxy, cycloalkoxy; R4 = NH2 or NHR6, where R6 is alkanoyl, alkylaminocarbonyl, or carbalkoxy; Q is a 3-9 atom (un)saturated alkylene chain optionally containing 1-3 heteroatoms O, S, SO, or SO2], including methods for their synthesis and use in pharmaceutical compns. for therapeutic or prophylactic prevention or treatment of hepatitis C virus (HCV) infection. Thus, 3,13-diazatricyclo[11.3.0.04,6]hexadec-7-ene derivative II was prepared by a multistep procedure and assayed for inhibition of HCV NS3/4A protease (IC50 < 5 μM).

L7 ANSWER 12 OF 21 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:338309 HCAPLUS
DOCUMENT NUMBER: 139:143358
TITLE: Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection
AUTHOR(S): Tsantrizos, Youla S.; Bolger, Gordon; Bonneau, Pierre; Cameron, Dale R.; Goudreau, Nathalie; Kukolj, George; LaPlante, Steven R.; Llinas-Brunet, Montse; Nar, Herbert; Lamarre, Daniel
CORPORATE SOURCE: Departments of Chemistry and Biological Sciences Research and Development, Boehringer Ingelheim (Canada) Ltd., Laval, QC, H7S 2G5, Can.
SOURCE: Angewandte Chemie, International Edition (2003), 42(12), 1356-1360
CODEN: ACIEF5; ISSN: 1433-7851
PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A novel class of selective inhibitors of the hepatitis C virus NS3 protease, an enzyme which is essential for viral replication in vivo, was developed. The inhibitors are based on the structure-activity relationship between a substrate-based peptidomimetic ligand and the HCV NS3 serine protease. The designed HCV inhibitor and its saturated analogs are the first inhibitors of the NS3 protease which inhibit HCV RNA replication in the cell-based replicon assay. In addition, they are orally absorbed and stable to metabolic breakdown. Thus, these compds. show many of the desirable properties of a druglike archetype and could lead t a clin. useful antiviral agent for the treatment of hepatitis C viral infections in humans.
REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 13 OF 21 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:725652 HCAPLUS
DOCUMENT NUMBER: 133:296659

TITLE: Preparation of macrocyclic peptides active against the hepatitis C virus
INVENTOR(S): Tsantrizos, Youla S.; Cameron, Dale R.; Faucher, Anne-marie; Ghiro, Elise; Goudreau, Nathalie; Halmos, Teddy; Llinas-brunet, Montse
PATENT ASSIGNEE(S): Boehringer Ingelheim (Canada) Ltd., Can.
SOURCE: PCT Int. Appl., 154 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000059929	A1	20001012	WO 2000-CA353	20000403 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2367127	AA	20001012	CA 2000-2367127	20000403 <--
CA 2367127	C	20050118		
EP 1169339	A1	20020109	EP 2000-913999	20000403 <--
EP 1169339	B1	20040929		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000009599	A	20020115	BR 2000-9599	20000403 <--
TR 200102878	T2	20020121	TR 2001-200102878	20000403 <--
EE 200100516	A	20021216	EE 2001-516	20000403 <--
NZ 515286	A	20040227	NZ 2000-515286	20000403 <--
EP 1437362	A1	20040714	EP 2004-9264	20000403 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
AT 277945	E	20041015	AT 2000-913999	20000403 <--
AU 778390	B2	20041202	AU 2000-35480	20000403 <--
PT 1169339	T	20041231	PT 2000-913999	20000403 <--
RU 2247126	C2	20050227	RU 2001-129709	20000403 <--
ES 2230084	T3	20050501	ES 2000-913999	20000403 <--
ZA 2001007862	A	20040401	ZA 2001-7862	20010925 <--
BG 105970	A	20020531	BG 2001-105970	20011002 <--
HR 2001000720	A1	20021231	HR 2001-720	20011004 <--
NO 2001004857	A	20011031	NO 2001-4857	20011005 <--
HK 1042714	A1	20050401	HK 2002-104507	20020618 <--

PRIORITY APPLN. INFO.:	US 1999-128011P	P	19990406 <--
	EP 2000-913999	A3	20000403 <--
	WO 2000-CA353	W	20000403 <--

OTHER SOURCE(S): MARPAT 133:296659
GI



I

AB Macrocyclic peptides I [W = CH or N; R21 = H, halo, alkyl, cycloalkyl, haloalkyl, alkoxy, cycloalkoxy, hydroxy, or an amino group; R22 = H, halo, alkyl, cycloalkyl, haloalkyl, thioalkyl, alkoxy, cycloalkoxy, alkoxyalkyl, cycloalkyl, aryl or heteroaryl; R3 = hydroxy, NH2, aryl- or heteroarylamino, NHCOR32, CONHR32, CO2R32, where R32 is alkyl or cycloalkyl; D is a 5 to 10-atom saturated or unsatd. alkylene chain optionally containing one to three heteroatoms independently selected from: O, S, or NH or substituted imino; R4 = H or from one to three substituents at any carbon atom of chain D; A is an amide or carboxylic acid group or a pharmaceutically acceptable salt or ester; two diastereomers may exist at the cyclopropane moiety] were prepared which are active in-vitro and in cellular assays against the NS3 protease of the hepatitis C virus . Thus, macrocyclic peptide I [W = N; R21, R22, R4 = H; A = CO2H; R3CH-D = (S)-(Me3CO2CNH)CH(CH2)3CH:CH(CH2)2-E (syn to acid)] was prepared and showed IC50 > 0.1 μM in the full-length NS3-NS4A heterodimer protein fluorogenic assay.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 14 OF 21 USPATFULL on STN

ACCESSION NUMBER: 2005:183951 USPATFULL

TITLE: Composition for the treatment of infection by Flaviviridae viruses

INVENTOR(S): Lamarre, Daniel, Laval, CANADA
Lagace, Lisette, Laval, CANADA

PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Ingelheim, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005159345	A1	20050721	
APPLICATION INFO.:	US 2003-687204	A1	20031016	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2002-421900P	20021029 (60)	<--
	US 2003-442769P	20030127 (60)	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MICHAEL P. MORRIS, BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY RD, P O BOX 368, RIDGEFIELD, CT, 06877-0368, US

NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 1423
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions, use, article of manufacture and method for the treatment of a mammal infected with a virus of the Flaviviridae family are provided comprising administration to the infected mammal of a compound having the Formula I: ##STR1## wherein,

A is selected from: C.sub.1 to C.sub.6 alkyl and C.sub.3 to C.sub.6 cycloalkyl; and B is selected from: phenyl or thiazolyl, both of which optionally substituted with a group selected from NH(R.sup.1) and NH(CO)R.sup.1, wherein R.sup.1 is C.sub.1 to C.sub.6 alkyl; R is OH or a sulfonamide derivative; or a pharmaceutically acceptable salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 15 OF 21 USPATFULL on STN
ACCESSION NUMBER: 2005:87814 USPATFULL
TITLE: Macrocyclic peptides active against the hepatitis C virus
INVENTOR(S): Llinas-Brunet, Montse, Dollard-des-Ormeaux, CANADA
Bailey, Murray D., Pierrefonds, CANADA
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Ingelheim, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005075279	A1	20050407	
APPLICATION INFO.:	US 2003-686755	A1	20031016	(10)

	NUMBER	DATE		
PRIORITY INFORMATION:	US 2002-421414P	20021025	(60)	<--
	US 2002-433820P	20021216	(60)	<--
	US 2003-442768P	20030127	(60)	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MICHAEL P. MORRIS, BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY RD, P O BOX 368, RIDGEFIELD, CT, 06877-0368
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
LINE COUNT: 1163
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of formula (I): ##STR1##

wherein R.sup.1 is (C.sub.1-8)alkyl, (C.sub.3-7)cycloalkyl, {(C.sub.1-6)alkyl-(C.sub.3-7)cycloalkyl} or Het, which are all optionally substituted from 1 to 3 times with halo, cyano, nitro, O--(C.sub.1-6)alkyl, amido, amino or phenyl, or R.sup.1 is C.sub.6 or C.sub.10 aryl which is optionally substituted from 1 to 3 times with halo, cyano, nitro, (C.sub.1-6)alkyl, O--(C.sub.1-6)alkyl, amido, amino or phenyl; or a pharmaceutically acceptable salt thereof, useful as an inhibitor of the HCV NS3 protease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 16 OF 21 USPATFULL on STN
ACCESSION NUMBER: 2004:178939 USPATFULL

TITLE: Potent inhibitor of HCV serine protease
INVENTOR(S): Chen, Shirlynn, Somers, NY, UNITED STATES
Croenlein, Jens Oliver, Mittelbiberach, GERMANY, FEDERAL REPUBLIC OF
Nehmiz, Gerhard, Biberach, GERMANY, FEDERAL REPUBLIC OF
Steinmann, Gerhard, Erbach-Bach, GERMANY, FEDERAL REPUBLIC OF
Gunn, Jocelyn Abella, Hamden, CT, UNITED STATES
Costa, Phuong Do, Danbury, CT, UNITED STATES
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, UNITED STATES (U.S. corporation)
Boehringer Ingelheim Pharma GmbH & CO. KG, Ingelheim, GERMANY, FEDERAL REPUBLIC OF (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004138109	A1	20040715	
APPLICATION INFO.:	US 2003-663220	A1	20030916	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2002-414940P	20020930 (60)	<--
	US 2002-421904P	20021029 (60)	<--
	US 2002-433834P	20021216 (60)	<--
	US 2003-443662P	20030130 (60)	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P O BOX 368, RIDGEFIELD, CT, 06877
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
LINE COUNT: 1072
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are oral pharmaceutical compositions, kits and methods of treating and preventing Hepatitis C Viral (HCV) infections wherein the following Compound (1), a potent inhibitor of HCV serine protease, or a pharmaceutically acceptable salt thereof, is administered in a selected dosage range: ##STR1##

Also disclosed are the use of a compound of formula (1), or a pharmaceutically acceptable salt thereof, as a control substance for validating an HCV replication assay and also as a control substance for determining the relative effectiveness of one or more substances, alone or in combination, to inhibit the replication of HCV.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 17 OF 21 USPATFULL on STN
ACCESSION NUMBER: 2004:145082 USPATFULL
TITLE: Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions
INVENTOR(S): Simianer, Stefan, Mittelbiberach, GERMANY, FEDERAL REPUBLIC OF
Bilbault, Pascal, Reims, FRANCE
Cappola, Michael L., Wilton, CT, UNITED STATES
Way, Susan Lynn, Danbury, CT, UNITED STATES
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT (non-U.S. corporation)
Boehringer Ingelheim France, Paris, FRANCE (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004110755	A1	20040610	
APPLICATION INFO.:	US 2003-638702	A1	20030811	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2002-403115P	20020813 (60)	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P O BOX 368, RIDGEFIELD, CT, 06877
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
LINE COUNT: 4651
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to pharmaceutical combinations therapies based on p38 kinase inhibitors and another active ingredient, pharmaceutical compositions comprising such combinations, processes for preparing them and their use in the treatment of cytokine mediated diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 18 OF 21 USPATFULL on STN
ACCESSION NUMBER: 2004:51441 USPATFULL
TITLE: Inhibitors of hepatitis C virus
INVENTOR(S): Campbell, Jeffrey Allen, Cheshire, CT, UNITED STATES
Good, Andrew Charles, Wallingford, CT, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004038872	A1	20040226	
	US 6867185	B2	20050315	
APPLICATION INFO.:	US 2002-317451	A1	20021212	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2002-382103P	20020520 (60)	<--
	US 2001-344080P	20011220 (60)	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
LINE COUNT: 5050
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to macrocyclic compounds, methods for making these compounds, pharmaceutical compositions and the therapeutic or prophylactic use of these compounds by administering said compounds to mammals to prevent or treat hepatitis C virus (HCV) infection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 19 OF 21 USPATFULL on STN
ACCESSION NUMBER: 2004:2425 USPATFULL
TITLE: Macrocyclic peptides active against the hepatitis C virus
INVENTOR(S): Tsantrizos, Youla S., Saint-Laurent, CANADA
Cameron, Dale R., Rosemere, CANADA

Faucher, Anne-Marie, Oka, CANADA
Ghiro, Elise, Laval, CANADA
Goudreau, Nathalie, Mont-Royal, CANADA
Halmos, Teddy, Laval, CANADA
Llinas-Brunet, Montse, Dollard-des-Ormeaux, CANADA
PATENT ASSIGNEE(S): Boehringer Ingelheim (Canada) Ltd., Laval, CANADA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004002448	A1	20040101
APPLICATION INFO.:	US 2003-358726	A1	20030205 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-760946, filed on 16 Jan 2001, PENDING Continuation-in-part of Ser. No. US 2000-542675, filed on 3 Apr 2000, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-128011P	19990406 (60) <--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY RD, P O BOX 368, RIDGEFIELD, CT, 06877
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 1
LINE COUNT: 3518
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention covers macrocyclic compounds of formula I active in-vitro and in cellular assays against the NS3 protease of the hepatitis C virus. ##STR1##

wherein W, R.sup.21, R.sup.22, R.sup.3, R.sup.4, D and A are as defined herein, or a pharmaceutically acceptable salt or ester thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 20 OF 21 USPATFULL on STN
ACCESSION NUMBER: 2003:277201 USPATFULL
TITLE: Pharmaceutical compositions for hepatitis C viral protease inhibitors
INVENTOR(S): Chen, Shirlynn, Somers, NY, UNITED STATES
Mei, Xiaohui, Highland Mills, NY, UNITED STATES
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003195228	A1	20031016
	US 6828301	B2	20041207
APPLICATION INFO.:	US 2003-357919	A1	20030204 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-355694P	20020207 (60) <--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P O BOX 368, RIDGEFIELD, CT, 06877
NUMBER OF CLAIMS: 45
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)

LINE COUNT: 1696
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are pharmaceutical compositions of hepatitis C viral protease inhibitors having improved bioavailability, and methods of using these compositions for inhibiting the replication of the hepatitis C virus (HCV) and for the treatment of an HCV infection. These compositions include co-solvent systems, lipid based systems, solid dispersions and granulations, and all comprise the hepatitis C viral protease inhibitor, at least one pharmaceutically acceptable amine and optionally one or more additional ingredients.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 21 OF 21 USPATFULL on STN
ACCESSION NUMBER: 2003:258310 USPATFULL
TITLE: Macrocyclic peptides active against the hepatitis C virus
INVENTOR(S): Llinas-Brunet, Montse, Laval, CANADA
Gorys, Vida J., Laval, CANADA
PATENT ASSIGNEE(S): Boehringer Ingelheim (Canada) Ltd., Laval, CANADA (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003181363	A1	20030925	
APPLICATION INFO.:	US 2002-320978	A1	20021217	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	CA 2002-2369711	20020130	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY RD, P O BOX 368, RIDGEFIELD, CT, 06877
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
LINE COUNT: 1345
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of formula I: ##STR1##

wherein R.sup.1 is hydroxy or NHSO.sub.2R.sup.1A wherein R.sup.1A is (C.sub.1-8)alkyl, (C.sub.3-7)cycloalkyl or {(C.sub.1-6)alkyl-(C.sub.3-7)cycloalkyl}, which are all optionally substituted from 1 to 3 times with halo, cyano, nitro, O(C.sub.1-6)alkyl, amido, amino or phenyl, or R.sup.1A is C.sub.6 or C.sub.10 aryl which is optionally substituted from 1 to 3 times with halo, cyano, nitro, (C.sub.1-6)alkyl, O(C.sub.1-6)alkyl, amido, amino or phenyl; R.sup.2 is (C.sub.5-6)cycloalkyl and R.sup.3 is cyclopentyl; or a pharmaceutically acceptable salt thereof, useful as inhibitors of the HCV NS3 protease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L2	7	"6608027".pn. or "6231887".pn. or "20030195228".pn.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2006/02/13 15:36
L3	290675	sodium adj hydroxide	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2006/02/13 15:36
L4	148946	potassium adj hydroxide	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2006/02/13 15:36
L5	166973	sodium adj2 carbonate	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2006/02/13 15:36
L7	48284	aluminum adj hydroxide	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2006/02/13 15:37
L8	29305	magnesium adj hydroxide	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2006/02/13 15:37
L9	420	magnesium adj aluminum adj hydroxide	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2006/02/13 15:37
L10	457143	l9 or l8 or l7 or l5 or l4 or l3	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2006/02/13 15:41
L11	28913	l10 same base same ph	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2006/02/13 15:38
L12	387	l11 same lubricant	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2006/02/13 15:38

L13	2386	l11 same pharmaceutical	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2006/02/13 15:38
L14	57	l12 and l13	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2006/02/13 15:38
L15	26	l9 same l8 same l7 same l5 same l4 same l3	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2006/02/13 15:41
L16	2	("2001/0024658").URPN.	USPAT	AND	ON	2006/02/13 15:50
L17	4	amine same oil same (hydrophilic adj solvent) same polymer same surfactant	USPAT	AND	ON	2006/02/13 15:52
L19	91361	ethanolamine or diethanolamine or triethanolamine or tromethamine or (tris adj hydroxymethyl adj aminomethane) or (ethylene adj diamine) or dimethylaminoethanol or meglumine	USPAT	AND	ON	2006/02/13 15:53
L20	0	ethanolamine diethanolamine triethanolamine tromethamine (tris adj hydroxymethyl adj aminomethane) (ethylene adj diamine) dimethylaminoethanol meglumine	USPAT	SAME	ON	2006/02/13 15:54
L21	0	ethanolamine diethanolamine triethanolamine tromethamine (tris adj hydroxymethyl adj aminomethane) (ethylene adj diamine) dimethylaminoethanol meglumine	USPAT	AND	ON	2006/02/13 15:54
L22	0	l21 and l10	USPAT	AND	ON	2006/02/13 15:54
L23	46395	l19 and l10	USPAT	AND	ON	2006/02/13 15:54
L24	8	l15 same l19	USPAT	AND	ON	2006/02/13 16:45
L27	2	wo-2004039833-$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2006/02/13 16:45
L28	2	wo-2004037855-$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2006/02/13 16:46

L29	2	wo-2004030670-$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2006/02/13 16:46
L30	3	"6248776".pn. or "6476066".pn.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2006/02/13 16:46
L31	2	wo-2004014387-$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2006/02/13 16:47
L33	2	"20030224977".pn.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2006/02/13 16:47
L34	3	"6608027".pn.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2006/02/13 16:48
L37	1	wo-2003066103-$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2006/02/13 16:49
L38	1	wo-2003064455-$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2006/02/13 16:48
L39	1	wo-2003053349-$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2006/02/13 16:49
L42	2	"20050159345".pn.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2006/02/13 16:51
L48	2	"20040038872".pn.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2006/02/13 16:53

L49	2	"20040110755".pn.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2006/02/13 16:52
L50	2	"20040138109".pn.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2006/02/13 16:52
L51	2	"20050075279".pn.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2006/02/13 16:53
L52	2	"20040002448".pn.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2006/02/13 16:53
L53	2	"20030195228".pn.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2006/02/13 16:54
L54	2	"20030181363".pn.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2006/02/13 16:54
L55	26	l27 l28 l29 l30 l31 l33 l34 l37 l38 l39 l42 l49 l50 l51 l48 l52 l53 l54	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/02/13 16:55
S2	1	wo-200059929-$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2006/02/13 14:27
S3	1	2000-672620.NRAN.	DERWENT	AND	ON	2006/02/13 14:08
S5	1	wo-2003059929-$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2006/02/13 14:29
S6	1	2003-618175.NRAN.	DERWENT	AND	ON	2006/02/13 14:28

S7	1	wo-2003066103-$.did.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	AND	ON	2006/02/13 15:33